Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 February 2020 | Story Michelle Nöthling | Photo Johan Roux
Fragility read more
The colloquium brought together students, staff and administration to work together on resolving ongoing problems within the higher education sector.

Where does resilience – or the lack thereof – in higher education come from? What does resilience and fragility even mean? These were some of the core issues examined during a recent symposium titled ‘Fragility and Resilience: Facets, Features and (Trans) Formations in Higher Education’. The Unit for Institutional Change and Social Justice hosted the event from 28 to 31 January 2020 on the University of the Free State (UFS) Bloemfontein Campus. The symposium – now in its seventh year – is a collaborative endeavour between the UFS, the University of California, Los Angeless (UCLA), and the Vrije Universiteit Amsterdam (VUA) to learn and share knowledge. “The real aim of the symposium is to address diversity and transformation issues from different contexts so that we can compare and contrast and learn best practices,” said Dr Dionne van Reenen, Senior Researcher in the Unit for Institutional Change and Social Justice, and convener of the event. 

Against the Psychologisation of Resilience

In a keynote address, Prof Michalinos Zembylas from the Open University of Cyprus argued against the potential psychologisation of resilience. According to Prof Zembylas, the concept of resilience is often framed as the psychological capacity of the individual to thrive through vulnerability and change. Such a view inevitably places the responsibility for success or failure on the shoulders of the individual and ignores the collusion between systems of oppression and structural inequalities. “The concept of resilience has become part and parcel of neoliberal governmentality – a growing emphasis on autonomous and reflexive individuals who have the capacity to conduct their own risk assessments and pursue their own life opportunities,” Prof Zembylas said. Therefore, within this neoliberalist ideology with its emphasis on the individual, people are led to believe that they need to continually adapt to threats that are essentially out of their control. A resilient person is, in other words, someone who permanently transforms themselves to accommodate the world without the possibility of actually changing that world. 

What impact does this have on higher education? Prof Zembylas noted that a neoliberalist perception of resilience discourages students “from imagining themselves as political agents who could collectively work to challenge harmful or unjust working and life practices”. Although universities use a great variety of tools and interventions to address students’ fragility, these approaches often focus on the vulnerability of the individual. Instead, Prof Zembylas proposed a shift towards an ontology that regards vulnerability as produced by conditions of oppression. A pedagogy of oppression is different from a pedagogy of vulnerability, since “instead of focusing on vulnerabilities, you would rather instil confidence in subjects to say no to abuse of power”.

The nature and role of student hope and meaning in goal setting and life satisfaction

Prof Itumeleng Khumalo, Associate Professor in the Department of Psychology at the UFS, delivered the following day’s keynote address. “Many studies concerned with youth have focused on their fears, worries and anxieties, instead of positive functioning and satisfaction with life,” Prof Khumalo remarked. In contrast, he opted to look at how hope and meaning shape students’ goals for higher education. Focusing on hope and meaning, however, does not deny the fact that South African students, in particular, are faced with substantial challenges. The majority of students enrolling in higher education in South Africa are first-generation entrants. Seventy percent of students do not have a graduate parent, and 45% do not have any family members who graduated. Most of these students are burdened with fears of failing, financial problems, difficulties with accommodation, worries about family members, inadequate knowledge regarding digital technology, and lack of support. 

Despite the above, a study by Prof Khumalo and Dr Angelina Wilson Fadiji showed that 85% of their student sample expected life would get better as a result of their education. The vast majority of students indicated that their main goal was to attain employment and build a career as a result of tertiary education. Students believe that getting an education will afford them opportunities to get ahead in life and enable them to become financially independent. “The perceived linear pathway from education to a better and successful life remains the dominant belief among these students, rendering education an undisputed panacea,” Prof Khumalo said. Ultimately, hope and meaning are sources of direction and motivation, and institutions of higher learning play a crucial role in human capacity development.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept